Dual incretin receptor research

Tirzepatide

Single-molecule dual GIP and GLP-1 receptor agonist documented across five presentations.

Explore presentation-specific analytical records covering identity, purity, measured content, lot traceability and downloadable Certificates of Analysis.

Certified presentations
Product information
Royal Pharma Tirzepatide vial
Selected record15 mg

Product-family image supplied by Royal Pharma. Certified presentations are identified by their individual COA records below.

Product authentication

Authenticity, built into every product.

Powered by NFC. Secured by blockchain. Verified instantly.

Each Royal Pharma product carries a unique NFC-enabled microchip connected to the brand's proprietary blockchain authentication environment, creating a secure, traceable and tamper-resistant digital identity.

01
Unique identity

A product-linked NFC identity designed for one-tap verification.

02
Secure verification

A blockchain-secured record supporting authenticity and traceability.

03
Batch documentation

Presentation-specific COAs document identity, purity, measured content and lot information.

Product information

Dual-incretin receptor research, documented by batch.

Tirzepatide is a 39-amino-acid peptide engineered to engage both GIP and GLP-1 receptor pathways. This research-only Royal Pharma page connects five presentations to their individual identity, purity and content records.

01

Research class

Dual GIP / GLP-1 receptor agonist
02

Documentation status

Research reference compound
03

Reference CAS

2023788-19-2
04

Physical form

White lyophilised powder

Research profile

One sequence. Two incretin receptors.

Receptor-pharmacology research examines how combined GIP and GLP-1 activity differs from single-pathway agonism. The supplied certificates concern only the submitted samples and do not provide clinical-use instructions.

GIP
GIP receptor pathway

One arm of the molecule's dual incretin receptor profile.

GLP-1
GLP-1 receptor pathway

The second receptor arm included in the dual-agonist design.

DUAL
Extended peptide design

The 39-residue sequence includes a lipid-associated extension strategy.

Quality documentation

Certificate of Analysis

Choose a presentation to display the exact analytical record
supplied for that sample.

Select presentation
Selected COA

Tirzepatide · 15 mg

Purity99.71%
Measured content
15.11 mg
Identity
Tirzepatide
Lot
N/A
Appearance
White Lyophilized Powder
Accession number
2607080473
Search code
Received
03/01/2026
Reported
3/02/2026
For laboratory research use only.

The supplied certificates state that the tested materials are intended for research use only and are not approved for human or veterinary use, diagnostic, therapeutic or clinical applications. Results are specific to the submitted samples. This page does not provide medical advice, dosing or administration instructions.